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Innate lymphoid cells are an emerging family of effector cells that contribute to lymphoid organogenesis,
metabolism, tissue remodelling and protection against infections. They maintain homeostatic immunity at barrier
surfaces such as lung, skin and gut (Nature 464:1367–1371, 2010, Nat Rev Immunol 13: 145–149, 2013). Several
human and mouse studies suggest a role for innate lymphoid cells in inflammatory skin conditions including atopic
eczema and psoriasis. Here we review the innate lymphoid cell family and discuss their function in the skin and
during inflammation.
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Innate lymphoid cells
Recent advances in the field of immunology have identi-
fied a novel family of CD45 expressing haematopoietic
effector cells. These cells have phenotypical features of
lymphoid cells but lack rearranged antigen specific sur-
face receptors of adaptive immune cells and are termed
innate lymphoid cells (ILCs) [1]. ILCs are essential for
lymphoid organogenesis, metabolism, tissue homeostasis
and repair, protection against viral and helminth infec-
tions [2-4]. They reside in the blood, spleen, intestine,
liver, fat associated lymphoid clusters (FALC), and mes-
enteric lymph nodes of humans and mice. Their devel-
opment depends on the expression of the transcriptional
repressor Id2 that regulates the activity of helix-loop-
helix protein E47 and RORC. Cytokines that signal
through the common γ chain of IL-2 receptor and Jak3
are essential for their maintenance.
ILCs are thought to be able to influence adaptive im-
mune responses as they reside in the interface of T and
B cell zones in the splenic follicles of mice and can ex-
press co-stimulatory molecules essential for T cell prim-
ing and survival, including CD40 ligand and CD30
ligand [5]. Each distinct functional subset produces cyto-
kines that were previously thought to be specific to
adaptive immune system lineages. Based on their cyto-
kine profile and functional characteristics, they can be
divided into three main groups [1], although recent* Correspondence: Graham.ogg@ndm.ox.ac.uk
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Group 1 ILCs
The most studied prototype of this family is group 1
ILCs including NK cells and group 1 innate lymphoid
cells (ILC1) which were identified in 1975 and 2012, re-
spectively [7-9]. They express transcription factors T-bet,
Nfil3 (E4BP4) and Eomes [10], and IL-15 and IL-12 are
required for their development and function. NK cell
subsets include cytolytic effectors of the innate immune
system and can produce IFN-γ, TNF-α, MIP1-α, MIP1-β
and RANTES. They are believed to be responsible for
defence against intracellular pathogens, tumours and vi-
ruses, but may contribute to aberrant inflammation in
certain settings. Unlike NK cells, ILC1 lack granzyme B
and perforin but express CD103 [11] and CXCR3 [9].
IL-7Rα+ IL-12Rβ2+ IL-1R+ group 1 ILCs produce IFN-γ
in response to IL-12 and are enriched in inflamed muco-
sal tissue such as tonsils, intestine and in diseased tissue
including the lamina propria of patients with Crohn’s
disease [11] and inflamed lungs of patients with chronic
obstructive pulmonary disease (COPD) [12]. Interest-
ingly group 1 ILCs are absent from foetal gut and de-
velop after colonisation of the intestine with commensal
bacteria [9]. These findings indicate their potential role
in protection against certain bacteria in homeostatic
conditions and their involvement in the pathogenesis of
inflammatory bowel disease and COPD. The origin of
group 1 ILC is not clear; however several studies haveral Ltd. This is an Open Access article distributed under the terms of the Creative
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ate from NKp44+ group 3 ILC under the influence of IL-12
and IL-15 [9,13].
Group 2 ILCs
The production of key type 2 cytokines, IL-13, IL-4 and
IL-5 in response to epithelial cytokines IL-25 and IL-33
in Rag−/− mice led to the discovery of group 2 ILCs. In
2010, three separate groups reported lineage negative
cells (CD3, CD4, CD8α, TCRαβ, TCRɣδ, CD5, CD19,
B220, NK1.1, Ter119 (Ly76), Gr-1 (Ly6g), Mac-1 (Itgam),
CD11c (Itgax) and FcϵRIα) that expressed c-Kit (CD117)
and T1/ST2, CD90 (Thy-1), CD45 and IL-7Rα (CD127)
in mice. They were designated nuocytes [2], innate helper
type 2 (IHC) [14] and natural helper cells (NHC) [15] but
demonstrated similar functional characteristics. Concur-
rently, Saenz described a similar population of multi-
potent progenitor type 2 (MPP type2) cells but unlike
other populations, MPP type 2 cells exhibited progenitor
capacity and could differentiate to myeloid and lymphoid
lineage descendants [16]. Therefore, it has been speculated
that they might be precursors of group 2 ILCs [17]. Re-
cently the term ILC2 was proposed to group type 2 cyto-
kine producing ILC in to a single family [1]. Lack of
RORγt expression and IFN-ɣ production differentiate this
group of innate cells from LTi cells and ILC1, respectively.
ILC2s were described in fat associated lymphoid clusters
(FALC), mesenteric lymph nodes (mLN), intestine and gut
associated lymphoid tissues (GALT), liver and spleen.
Bearing IL-17RB (IL-17BR, IL-25R), ST-2 (IL-33R) and
TSLP receptors ILC2 cells respond to epithelial cytokines
including IL-25 (IL-17E), IL-33 and TSLP, by producing
type 2 cytokines as IL-13, IL-4, IL-5, IL-9.
Human ILC2s were discovered in healthy human lung
parenchyma and broncho-alveolar lavage (BAL) fluid of
patients receiving a lung transplant as lineage negative
cells (CD3, TCRαβ, CD11c, CD11b, CD56, CD19) that
express IL-7Rα and ST2 subunit of the IL-33 receptor
[18]. Spits et al. reported lineage negative (CD3, CD4,
CD11c, CD14, CD19, CD34, CD123, TCRαβ, TCRɣδ,
BDCA2, and FcεRI), CD45hi, CD127+ and CD117+ cells
in peripheral blood, foetal gut and inflamed nasal polyps
of patients with rhinosinusitis. They also express prosta-
glandin D2 receptor (CRTH2), CD161 (KLRB1), CD7
and CD25. In response to epithelial cytokines and IL-2
the cells produce large amounts of IL-13 and IL-5 but
not IL-17A or IL-22 [19,20].
ILC2 represent a vital source of IL-13 for expulsion of
the gut helminth, Nippostrongylus brasiliensis [2,15,16]
by inducing goblet cell hyperplasia, eosinophilia and in-
testinal smooth muscle cell contraction. ILC2 also con-
tribute to homeostasis and allergic responses in the
airways. Using IL-4+/eGFP IL-13+/Tom dual reporter mice,
it was shown that ILC2s were the major source of type 2cytokines in Ovalbumin induced allergy and after intra-
nasal administration of IL-25 and IL-33 [21]. Moreover,
depletion of lung resident ILC2 in mice after infection
with H1N1 influenza virus A resulted in impaired airway
epithelial integrity and lung function, with exaggerated
thermodysregulation and higher total protein concentra-
tion in the broncho-alveolar lavage (BAL) fluid. Such
function is predominantly mediated by amphiregulin
production by ILC2, a wound-healing modulator of the
epidermal growth factor family [18]. Recent studies dem-
onstrated mutual interaction between ILC2 and T cells
[22,23]. Activated T cells produce IL-2 that induces pro-
liferation and cytokine production of ILC2 [23]. ILC2 in
humans and mice express MHC-II and co-stimulatory
molecules CD80 and CD86. Co-culture of ILC2s and
T cells in the presence of antigen, induced TH2 differenti-
ation and type 2 cytokine production in T cells [22,23]. In
addition, ILC2 also enhance differentiation of polyclonally
activated naïve T cells to a TH2 phenotype in an MHC-
independent contact-dependent manner [23]. Further-
more, N. brasiliensis infection of two mouse models
deficient in ILC2 showed delayed worm expulsion and a
dramatic decrease in IL-13 and IL-5 producing CD4+
T cells. Moreover, IL-2 released from T cells promotes
ILC2 proliferation and cytokine production [22].
Group 3 ILCs
Group 3 ILCs include lymphoid tissue inducers (LTi cells),
NCR+ ILC3 (NK22, NCR22, ILC22) and NCR− ILC3
(ILC17) [24]. Group 3 ILCs are important in inflamma-
tion, anti-microbial protection, mucosal immunity and
homeostasis. LTi cells express c-Kit, IL-7Rα, IL-1R, IL-23R
and lymphotoxin-β (LTβ), CCR6, and aryl hydrocarbon re-
ceptor (AHR) [25]. They initiate lymphoid structure for-
mation and induce expression of VCAM-1 and ICAM-1
on mesenchymal cells through LTβR and TNFR signalling
during embryogenesis and produce IL-17A [26]. After
birth, LTi cells contribute to the formation of solitary
lymphoid follicles and Peyer’s patches. After birth splenic
LTi cells produce IL-22 and IL-17A [25] in response to
yeast cell wall product zymosan which suggests that they
contribute to host defence. Furthermore, they also support
class switching to IgA and are thus important for adaptive
immune responses [27].
Two phenotypically distinct RORɣt dependent subsets
of ILC3 were characterised recently, and based on the
expression of natural cytotoxicity receptors, NKp46 in
mice and NKp44 in human, they were divided into NCR+
[24] and NCR− ILC3 [1]. Postnatal NCR+ ILC3 derived
from tonsils largely produce IL-22 and small amounts of
IL-17. They are thymus independent and reside in the in-
testine, dermis, tonsils and mLNs. NKp44+ RORɣt+ IL-22+
are diminished in germ free mice which suggests that
their maintenance and functional properties are largely
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by RORɣt+ ILCs is essential in protection against Citro-
bacter rodentium induced acute colitis in mice [28]. Re-
cently it was shown that Notch-2-dependent CD103+
CD11b+ cDCs are a major source of IL-23 during early
stages of infection with Citrobacter rodentium. The
population expansion of these cells was mediated by
LTβR signalling [29]. The expression of IL-22 in NCR+
ILC3 is negatively regulated by the epithelial cytokine
IL-25 as intestinal inflammation and epithelial damage by
administration of dextran sodium sulfate (DSS) that con-
comitantly increased IL-23 and reduced IL-25, induced
population expansion and IL-22 production by RORɣt+
ILCs [30]. The NCR− ILC3 population in mice expresses
SCA-1, IL-23 receptor, transcription factor RORɣt and
high levels of Thy-1. The cells accumulate in the gut dur-
ing Helicobacter hepaticus induced colitis. Stimulation of
NCR− ILC3s with IL-23 induces production of IL-17 and
IFN-ɣ [3].Recent studies showed that group 3 innate
lymphoid cells can regulate adaptive immune responses.
NCR− ILC3 express high levels of major histocompatibility
complex class II (MHCII) whereas NKp46+ ILC3 express
minimal levels of MHCII. Although ILC3 can process and
present antigen, they cannot induce T cell proliferation of
naïve T cells as they lack co-stimulatory molecules, CD80,
CD86, and CD40. Instead they appear to reduce T cell re-
sponses to commensal flora. Lack of MHC II on RORɣt+
ILCs induces spontaneous mild colitis, splenomegaly,
shortened intestine and crypt elongation [31].
ILC2 origin and transcription factors
Group 2 innate lymphoid cells arise in bone marrow
from common lymphoid progenitors (CLP) at the
double-negative stage 1 (DN1) and stage 2 (DN2). Their
presence in thymus deficient Foxn1nu/nu (nude) mice
confirms that they do not require the thymus for their
development [20,32]. Unlike most previous studies that
categorized NK and LTi cells in group 1 and group 3
ILCs respectively, recent work by Constantinides et al.
showed a common ILC progenitor (ILCP) in foetal liver
and adult bone marrow that can differentiate into ILC1,
ILC2 and ILC3 but not NK and LTi cells. ILCP were Lin−
IL-7Rα+ c-Kit+ α4β7+ and phenotypically similar to pre-
cursors of LTi cells. High levels of PLZF, a transcription
factor associated with NKT cells, as well as high levels of
Id2, GATA3 and TOX were found in ILCP. PLZF+ ILCP
arise from an α4β7 IL-7Rα+ population from which NK
and LTi progenitors are also known to develop. However,
interestingly depletion of PLZF altered ILC development
but did not affect NK and LTi cells, which shows that NK
and LTi cells have distinct precursors [6].
ILC2s require IL-7, IL-33 and signalling through tyro-
sine kinase receptor Flt-3 [32]. Jak3−/− mice are deficient
of ILC2 which confirms their requirement for signallingthrough common γ chain of IL-2 [20]. T cell factor-1
(TCF-1) essential for normal T cell lineage specification
and is also required for development of ILC2. In Tcf7−/−
mice the frequency of ILC2 is 5% of wild type mice, and
the remaining ILC2 are functionally compromised. Tran-
sient Notch signalling is another vital requirement for
ILC2 development that acts upstream of TCF-1 but does
not require the HES-1 pathway [33]. Forced expression of
TCF-1 can bypass Notch requirement by up-regulating
GATA-3 expression. GATA-3 maintains the expression of
IL-17RB, IL-2R, IL-1RL1 receptors and production of
IL-13 and IL-5. Its effect is intrinsic and dose dependent
[33,34]. Upon activation with IL-33 or a combination of
IL-2 and IL-25, it binds to the IL-5 and IL-13 promoter in
a p38 dependent manner [35]. GATA-3 induces the ex-
pression STAT-5 and increases responsiveness to IL-33
and TSLP [36]. Unlike TH2 cells, the expression of
GATA3 and production of type 2 cytokines in the lung
resident ILC2 in mice are STAT-6 and STAT-3 independ-
ent [37]. STAT-6 regulates the proliferation of these cells
and induction of eosinophilia in response to Alternaria
challenge.
Consistent with the lymphoid origin of ILC2, the tran-
scription factor Ikaros is necessary for their development
[20]. Although in one report a trace of RAG-1 expres-
sion was detected in these cells, mature ILC2s do not
express any rearranged antigen receptors [38] and unlike
other members of ILC family, their development is
largely dependent on RORA but not RORC expression
[32]. The precise interaction between GATA-3 and
RORA is not clear; Mjösberg et al. showed that RORA is
not regulated by GATA-3 and these two transcription
factors possibly work in parallel during development of
ILC2, whereas Wolterink et al. observed the lack of
RORα expression in the absence of GATA-3 [34,36]. Al-
though RORA and GATA-3 have a pivotal role in devel-
opment of ILC2, RORA is not essential for cytokine
production and maintenance of mature ILC2 [35]. Lung
ILC2 were observed in germ free mice and therefore
thought to be independent of commensal bacteria for
their development [18]. Although a degree of plasticity
has been shown in ILC3 and ILC1 populations as a pro-
portion of RORɣt+ NKR+ LTi cells can down regulate
RORɣt and produce IFN-ɣ [13], it has yet to be deter-
mined whether ILC2 have any plastic characteristics.
ILC2 and skin
Kim et al. provided the first evidence on the presence of
an ILC2 population in mouse and human skin. In mice,
they reported a population of Lin− CD25+ ST2+ c-Kit+
CD127+ ICOS+ that did not express ILC3 associated
markers CD4, NKp46 and RORɣt. Although they found
a similar population in healthy human skin (Lin− CD25+
IL-33+) these cells were negative for CRTH2 and CD161,
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and they only acquired the expression of these markers
in atopic dermatitis (AD) lesions. Therefore it raised the
possibility that this population is either a distinct popu-
lation of ILCs in human skin or is in a different stage of
activation.
Later, the existence of ILC2 in human skin with the
same morphology as described in other organs was con-
firmed [39-41]. Skin resident ILC2 did not express com-
mon lineage markers (CD3, CD8, CD14, CD19, CD56,
CD11c, CD11b, FcɛRI, TCR-αβ, TCR-ɣδ and CD123)
but were positive for CD45, IL-7Rα, CRTH2, CD161,
c-Kit, CD25 and ICOS [39,40]. They expressed tran-
scription factors RORα and GATA-3 whereas no RORɣt
was detected [39]. ILC2 isolated from peripheral blood
express skin homing markers cutaneous lymphocyte
antigen (CLA), CCR10 [41] and the levels were further
up regulated in the skin resident ILC2 [39] (16.7% to
37% and 0.9% to 84%, respectively) which suggests that
similar to other organs, bone marrow derived ILC2 cir-
culate in the blood and can migrate to the skin. ILC2 ef-
fector functions are at least partly mediated through
cytokine receptors IL25R (IL-17RB), IL-33R (ST2) and
TSLP-R [39-42] (Figure 1). In an activated state, these
receptors are further up-regulated. IL-33 alone or in
combination with IL-25 and TSLP could increase IL-13
and IL-5 production in human skin resident ILC2 [39].Figure 1 ILC1, ILC2 and ILC3 interactions in human skin. ILC1s express
receptor KLRG1. In homeostatic conditions, the expression of adhesion mo
activation of ILC2s. NKp44− ILC3s are the main subset of ILC3 in healthy ski
expression of ST2, IL-17RB and TSLP-R, probably an activated phenotype. Th
produced by keratinocytes and PGD2 released by mast cells and other cells. C
a novel mechanism of sensing a dysfunctional barrier. The frequency of ILC1 a
NKp44+ ILC3s is increased in psoriatic skin lesions. They produce IL-22 when sIn another report the combination of IL-2 and TSLP in-
duced production of type 2 cytokines and addition of
IL-25 to this cytokine mixture further enhanced IL-13
production, indicative of a synergistic effect. This syn-
ergy was not observed with IL-33 [41]. Activation of skin
resident ILC2 promotes amphiregulin production, which
is a ligand for epithelial growth factor receptor (EGFR)
and regulates proliferation, apoptosis and migration of
epithelial cells, and therefore contributes to wound heal-
ing and tissue repair [39].
Roediger et al. demonstrated potential immunosurveil-
lance activity of ILC2 in mouse skin. They reported a
unique and abundant population of CD45+ CD11b−
CD90hi CD3− CD2− c-Kit− IL-17RB+ ILC2s in the dermis
of naïve mice and called them ‘dermal ILC2’ (dILC2).
Dermal ILC2 expressed integrin αEβ7 (CD103) and com-
prised 5-10% of CD45+ cells. Using 4C13R dual reporter
mice in which single alleles of IL-13 and IL-4 were
substituted with dsRed and AmCyan respectively, they
showed that homeostasis of the skin in the steady state
was mainly controlled by CD3− NK1.1− dermal ILC2 ra-
ther than TH2 cells as they were the main producers of
IL-13. Although the dermal ILC2 population was unable
to produce IL-4 under homeostatic conditions, the cells
acquired this capacity upon stimulation with TSLP. Fur-
thermore, intravital multiphoton microscopy showed that
CXCR6+ ILC2 are mainly aggregated in the close vicinityCD161. ILC2s express IL-17RB, ST2, CRTH2, TSLPR and an inhibitory
lecule E-cadherin on normal human keratinocytes inhibits the
n. ILC2s are enriched in atopic dermatitis lesions and show higher
ey express IL-13, IL-5, and IL-4 in response to IL-33, IL-25 and TSLP
oncurrently, the diminished expression of E-cadherin on keratinocytes is
nd ILC3 in AD lesions are similar to healthy skin. The frequency of
timulated with IL-23.
Salimi and Ogg BMC Dermatology 2014, 14:18 Page 5 of 8
http://www.biomedcentral.com/1471-5945/14/18of blood vessels. They constantly patrol the skin local
microenvironment with rapid migration (5 μm/min) but
with intermittent long interactions with dermal mast cells
that lasted 20 to 30 minutes. Interestingly mast cells were
not essential for development and maintenance of dermal
ILC2 as mast cell deficient mice (B6-KitW−sh/W−sh and
WBB6F1-KitW/W−v) had intact population of dermal ILC2,
but in the presence of mast cells, dermal ILC2 were able
to regulate them through IL-13.
Anti-CD90.2 antibody is routinely used to deplete
ILC2 in mice. This method has been successfully used in
the skin by Salimi et al. [39] and Kim et al. [42] al-
though Roediger et al. [20] could not deplete CD103+
dILC2 from the skin using this method and only the
ILC2 population in the spleen was depleted, which sug-
gests that CD103+ dILC2 population might represent a
distinct sub-population of ILC2 in the skin. Therefore
instead of using a depletion strategy to study ILC2
function in the skin, they activated dILC2 in vivo using
complexes of IL-2 and JES6-1. Consistent with their im-
munomodulatory function, dILC2 underwent proliferation
and produced large amounts of IL-13 and IL-5. IL-13 sup-
pressed the IgE dependent release of inflammatory cyto-
kines by mast cells in a dose dependent manner [20].
The interaction between ILC2 and mast cells is im-
portant in regulating allergic type responses. Human
ILC2 can respond to prostaglandin D2 (PGD2), a major
metabolite produced by mast cells and other cells. This
interaction is mediated through CRTH2 [40,43]. Activa-
tion of human ILC2 by PGD2 increased expression of
type 2 cytokines as well as IL-3, IL-8, IL-9, IL-21, GM-
CSF and CSF-1. Interestingly PGD2 can induce produc-
tion of IL-4 in human ILC2 which was not observed
following stimulation with IL-25 and IL-33 [39-41]. PGD2
stimulation can augment expression of IL-33 receptor
(ST2) and the IL-17A subunit of IL-25 receptor [40] and
enhance ILC2 responses to IL-33 and IL-25 [43]. Consist-
ent with their quick effector function, both PGD2 and
IL-33 induced rapid migration of ILC2. IgE activated mast
cell supernatant which contained endogenously synthe-
sized PGD2, mediated the same CRTH2-dependent ef-
fector functions such as cell migration and cytokine
production in human ILC2 as exogenous PGD2.
Innate lymphoid cells, atopic dermatitis and psoriatic skin
inflammation
Atopic dermatitis is a chronic, relapsing inflammatory
skin condition characterized by hypersensitivity reac-
tions to common environmental allergens. Given in-
creased levels of type 2 cytokines, IL-13, IL-4 and IL-5,
in acute atopic eczema lesions and enhanced production
of epithelial cytokines IL-33, IL-25 and TSLP, it is plaus-
ible that group 2 innate lymphoid cells contribute to the
pathogenesis of atopic dermatitis. Indeed, ILC2 werefound in higher proportions in the lesions of patients
with atopic dermatitis while the frequency of the cells
was similar in the blood of both healthy and atopic
individuals [39,42]. ILC2 in atopic lesions showed an ac-
tivated phenotype with higher expression of cytokine
receptors, IL-17B (IL-25R), ST2 (IL-33R) and TSLP re-
ceptor. Increased mRNA levels of IL-17RB, ST2, TSLPR,
CRTH2, RORA and AREG were detected in lesional skin
biopsies of AD patients [39]. Interestingly sampling the
skin with or without intra epidermal delivery of house
dust mite (HDM) using a suction blister technique in
humans, showed that ILC2 infiltrate in to the skin in re-
sponse to allergen challenge in allergic individuals. A
similar effect was seen after subcutaneous administration
of HDM extract in mice.
A possible mechanism of skin barrier sensing was de-
scribed for activated ILC2 in atopic dermatitis lesions.
ILC2 express the KLRG1 receptor that upon interaction
with its ligand, E-cadherin, conveys inhibitory signals.
KLRG1 is up-regulated in response to ILC2 stimulating
cytokines. KLRG1 ligation to E-cadherin in a plate-
bound assay reduced production of type 2 cytokines,
IL-13 and IL-5, and diminished amphiregulin expression
and decreased GATA-3 expression. It is speculated that
in healthy tissues expressing E-cadherin, ligation to
KLRG1 regulates ILC2 responses. There is known to be
a significant down-regulation of E-cadherin on keratino-
cytes in AD lesions which may reduce inhibitory signals
to ILC2 and lead to production of type 2 cytokines
(Figure 1). The type 2 cytokines may contribute to cuta-
neous inflammation by down-regulating filaggrin and
anti-microbial peptides [44].
Group 2 innate lymphoid cells contribute to inflammation
in mouse models of AD-like inflammation. hK14mIL33tg
mice in which IL-33 is expressed under the keratin 14 pro-
moter developed spontaneous atopic dermatitis-like in-
flammation of the skin at 6–8 weeks of age in specific
pathogen-free (SPF) conditions. Similar to AD lesions,
the pattern of IL-33 expression in this model was con-
fined to the epidermal cell nuclei. Dermatitis lesions in
hK14mIL33tg mice were associated with a substantial in-
crease in the concentration of IL-13, IL-5, RANTES/
CCL5 and Eotoxin 1/CCL11, whereas the levels of TSLP,
IFN-γ and TNF-α were not altered. Increased degranulat-
ing IgE+ c-Kit+ mast cells as well as a significant infiltra-
tion of eosinophils were observed in the lesions and
blood of transgenic mice (7.4 and 4.5 fold higher expres-
sion compared to wild type mice respectively). Concur-
rently skin lesions and regional lymph nodes were
enriched for Lin− ST2+ Sca-1+ ILC2 producing IL-5 and
IL-13 [45].
Interestingly treatment of Rag1−/− mice with IL-2 and
anti-IL-2 complex (JES6-1) for 2–3 weeks induced spon-
taneous skin inflammation around ears, eyes, mouth and
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and increased degranulation of mast cells were observed
in these lesions which were caused in part by dILC2.
dILC2 showed an activated phenotype with higher ex-
pression of CD25, ICOS, CD69, ST2 and enhanced pro-
duction of IL-13 and IL-5 [20].
Topical application of a form of vitamin D3, calcipo-
triol (MC903), induces ear thickening, xerosis and histo-
pathological changes comparable to AD lesions and is
recognized as an experimental murine model of atopic
dermatitis. Coincident with ear thickening, increased in-
filtration of ILC2 was observed in the ear pinna and
draining lymph nodes of treated mice [39,42] which was
independent of adaptive immunity as Rag1−/− mice still
developed AD-like inflammation. Treatment of Rorc−/−
mice with calcipotriol induced the same level of inflam-
mation which ruled out the involvement of RORɣt
dependent ILC3s [42]. Depleting ILC2 using anti-CD90.2
[39,42] or anti-CD25 antibodies [42] in Rag1−/− mice
significantly ameliorated inflammation and histopatho-
logical changes observed in this model. To eliminate
the possibility of involvement of other cell types that
potentially express CD90.2 antigen, Salimi et al. used
RORα−/− bone marrow chimera mice that had sig-
nificantly lower numbers of ILC2s. Absence of ILC2s
strongly correlated with reduced ear swelling in this
model [39].
The hierarchal significance of ILC2 inducing epithelial
cytokines IL-25, IL33 and TSLP was established using
IL-17RB−/− IL-1RL1−/− and TSLPR−/− respectively back-
crossed to BALB/c and C57BL/6 strain backgrounds. In
cytokine receptor deficient mice generated on a BALB/c
strain background, the greatest protection against calci-
potriol induced inflammation was observed in mice lack-
ing IL-25 signalling pathway followed by IL-1RL1
deficient mice. The reduction in ear swelling correlated
with a decreased frequency of ILC2s in ear pinna and
draining lymph nodes. TSLPR deficient BALB/c mice
showed a modest reduction in ILC2 numbers and ear in-
flammation. Surprisingly, the C57BL/6 strain back-
ground showed greater dependency on TSLP signalling
pathway with a lower but significant role for IL-25 and
IL-33 signalling pathways in inducing AD-like inflamma-
tion compared to the BALB/c background [39].
It is noteworthy to mention that as well as ILC2s, pop-
ulations of NCR− ILC3 (26.5 ± 8.6%) and CD161+ ILC1
(24.8 ± 11.0% of CD45+ Lin− CD127+ ILC) were ob-
served in normal human skin [41] (Figure 1). There is a
noticeable population of NKp44+ ILC3s in cultured
dermal explants, although rare in freshly isolated cells.
NCR+ ILC3s differentiated from NCR− ILC3 upon cul-
ture with IL-23, IL-1β and express IL-22.
Blood and lesional skin biopsies of patients with psori-
atic skin inflammation showed enrichment of NCR+ILC3 although similar frequencies of CD161+ ILC1 and
CRTH2+ ILC2 were observed [41,46,47] (Figure 1).
These cells were an innate source of IL-22. One report
found that the frequency of NKp44+ ILC3 correlated
with disease severity using PASI score [41] whereas an-
other report could not show a similar finding [46].
Treatment of one psoriatic patient using anti-TNF mono-
clonal antibody (adalimumab) showed substantial drop
(75%) in frequency of NKp44+ ILC3 and equivalent in-
crease in population of NCR− ILC3s. This reduction in-
versely correlated with disease severity (PASI score 21.2 to
13.6) which shows the potential importance of NCR+
ILC3 in the pathogenesis of psoriasis.
Conclusions
In the skin, innate lymphoid cells comprise ILC1, ILC2
and ILC3 populations [41,46,47]. Group 2 innate lymph-
oid cells express CD45, CRTH2 and IL-7Rα while nega-
tive for common lineage markers. Bearing receptors for
epithelial cytokines and lipid mediators, they produce
IL-13, IL-5, IL-4 and IL-9 in response to IL-33, IL-25,
TSLP and PGD2 [39,40]. In the skin, ILC2s express skin
homing markers and play a role in type 2 mediated in-
flammation. Indeed, a higher frequency of ILC2 with an
activated phenotype was observed in the lesional skin bi-
opsies of patients with atopic dermatitis and established
mouse models of atopic dermatitis supported their con-
tribution to the pathogenesis of this disease [39,42,45].
Therefore ILC2s and their activating cytokines or lipid
mediators may be new targets for the treatment of atopic
dermatitis.
Although research in the field of innate lymphoid cells
is moving at a fast pace, many important questions re-
garding the role of ILC in health and disease still remain
unanswered. Detailed interactions of ILC2 with other
cell types, including epithelial cells, keratinocytes, fibro-
blasts, and other cells of the innate and adaptive im-
mune systems would provide a better understanding of
the extent of their contribution to homeostatic condi-
tions and disease pathogenesis. Detailed evaluation of
signals and mechanisms that regulate ILC activation and
inhibition during and after the onset of inflammation
and epithelial dysfunction, would help us to identify spe-
cific targets for therapeutic interventions.
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